درباره این اپیزود
In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, PA-C, is joined by Audrey Gibson, PA-C, for part three of their special RhAPP Up series covering key psoriatic arthritis updates from the 2026 EULAR Congress.
They begin by discussing real-world evidence on long-term treatment persistence with advanced therapies in psoriatic arthritis, highlighting how different mechanisms of action compare over time. The conversation focuses on what persistence and discontinuation rates may reflect in clinical practice and how real-world data can help inform treatment decisions.
The episode also reviews a phase 2B study of a selective TYK2 inhibitor, exploring its effects on inflammatory biomarkers and clinical response in patients with active psoriatic arthritis. The discussion highlights how emerging biomarker research may one day help guide more personalized treatment selection and improve outcomes.
Whether you're a rheumatology provider, advanced practice provider (APP), or other healthcare professional, this episode offers practical insights into real-world treatment patterns, emerging targeted therapies, and the future potential of biomarker-driven precision medicine in psoriatic arthritis care.
Thank you for watching, be sure to explore the three-part ILD RhAPP Up Series, and stay tuned for our upcoming Osteoporosis Abstract Reviews.
